drugset / Trial / NCT01779466

Daytime Impact Sleep Study

NCT01779466

Phase 2 Terminated 5 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This trial will investigate the relationship of sleep, daytime performance and nocturia in patients treated with Desmopressin or placebo. Male and Female patients will be administered Desmopressin or Placebo every day for 3 months.

Timeline

Start
2013-04
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Desmopressin Peptide Oral

Indications